Bionano Genomics (BNGO) Notes Payables (2023 - 2026)

Bionano Genomics (BNGO) has 4 years of Notes Payables data on file, last reported at $10.2 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables fell 22.15% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (down 22.15% YoY), and the FY2025 full-year result was $10.0 million, down 50.99% from the prior year.
• Notes Payables climbed to $10.2 million in Q1 2026, from $10.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $69.8 million in Q4 2023 to a low of $9.8 million in Q3 2025.
• A 4-year average of $20.8 million and a median of $14.0 million in 2024 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables slumped 70.83% in 2024 and decreased 22.15% in 2026, its largest moves.
• Tracing BNGO's Notes Payables over 4 years: stood at $69.8 million in 2023, then tumbled by 70.83% to $20.4 million in 2024, then plunged by 50.99% to $10.0 million in 2025, then gained by 1.73% to $10.2 million in 2026.
• Business Quant data shows BNGO's Notes Payables at $10.2 million in Q1 2026, $10.0 million in Q4 2025, and $9.8 million in Q3 2025.